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Bone Mineral Density in
Young Adult Survivors of
Acute Lymphoblastic
Leukemia
Thomas et al1 demonstrated a direct relation
between height and bone mineral density (BMD),
expressed as z-scores, in 74 young adult survivors of
childhood acute lymphoblastic leukemia (ALL).
Height z-score was the only significant predictor of low
BMD in their cohort in which the authors conclude
they have an increased prevalence of low bone mass.
Unfortunately, the authors have failed to appreci-
ate the technical limitations of dual-energy X-Ray
absorptiometry (DXA). Pediatric bone specialists have
long been aware of the direct relation between height z-
scores and BMD z-scores in healthy children and
adults.2 This relationship is purely technical, caused by
DXA not measuring true density (bone mass/volume),
but areal BMD (bone mass/projection area). The Inter-
national Society of Clinical Densitometry, therefore,
states that the DXA results in children need size cor-
recting.3 This DXA size relationship will, of course,
also apply to adults as well as children. The main obser-
vation by Thomas et al1 that lower BMD was associ-
ated with shorter stature, therefore, is a technical
necessity. In addition, the observed gender difference
in BMD can be easily explained because the men
(height z ¼ 1.06) were relatively shorter than the
women (height z¼0.35). Given that 36% of subjects
were short-normal (height z-score <1), the fact that
their non-size corrected BMD z-scores were above av-
erage is actually remarkable. Only 24% of subjects had
BMD z-scores <1, compared with the 15.9%
expected for healthy individuals (as per normal Gaus-
sian distribution). We predict that with appropriate
size correction, BMD of the subjects will be normal,
and relations with height and gender will disappear.
Undoubtedly, ALL causes bone disease, typically
within 2 years from diagnosis, comprising bone pain,
vertebral fractures, and avascular necrosis.4 However,
there is poor evidence of fractures as a ‘‘late’’ effect of
ALL, except in the case of pituitary or gonadal damage.
It would be helpful if Thomas et al could provide
details on fracture prevalence of their subjects, com-
pared with controls.
In summary, what the study by Thomas et al1 has
shown is that survivors of childhood ALL are shorter
than average, which may be a late effect of previous
treatment. What the study has not shown is a long-
term deficit in bone mass or strength.
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Reply to Bone Mineral
Density in Young Adult
Survivors of Acute
Lymphoblastic Leukemia
We appreciate Drs. Hogler and Shaw reiterating an
issue that we clearly discussed in our article1 as a study
limitation, ie, that dual-energy X-Ray absorptiometry
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(DXA) measurements do not take into account volu-
metric density and may not be reliable in individuals
who are very short. In the International Society for
Clinical Densitometry 2007 Adult and Pediatric Offi-
cial Positions published in Bone in December 2008,2 it
was recommended that areal bone mineral density
(BMD) should be used for correction in pediatric sub-
jects who have not completed puberty or linear growth.
However, all the subject in our study were adults, with
an average age of 30 years, and only 4 of the 18 subjects
with low BMD were below the 2.25 standard deviation
(SD) of age-specific, race-specific and sex-specific nor-
mative means for height. We, therefore, chose not to
statistically adjust their z-scores, given that there is no
clearly validated adult standard for doing so.
Unfortunately, we do not have data to compare
fracture occurrence in our study subjects, and fracture
risk is difficult to determine solely from DXA bone
mineral density estimates because there are no measures
of bone quality beyond bone mass.3 We agree that
focused research is needed on risk of fracture in long-
term survivors of pediatric cancer. We believe that our
study results suggest, but by no means prove, that adult
survivors of childhood acute lymphoblastic leukemia,
particularly males, are at elevated risk for early onset
osteopenia and that prudent medical surveillance is
justified.
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